Skip to main content

Advertisement

SpringerLink
Log in

Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Fluoropyrimidine plus platinum, followed by paclitaxel (PTX) plus ramucirumab is a recommended treatment strategy for advanced gastric cancer (AGC). We investigated how peripheral neuropathy (PN), induced by platinum in first-line chemotherapy, affected the tolerability of second-line chemotherapy with PTX (2nd-PTX).

Methods

The subjects were AGC patients who received second-line chemotherapy with PTX (2nd-PTX) after the failure of platinum-based chemotherapy between March 2015 and June 2018. We retrospectively reviewed PN severity, and dose reduction and/or discontinuation due to PN during 2nd-PTX, and compared the cumulative incidence of grade 2 PN between the two groups according to first-line chemotherapy containing oxaliplatin (L-OHP) or cisplatin (CDDP).

Results

The L-OHP and CDDP groups consisted of 50 patients each. PN severity before 2nd-PTX was grade 1/2 in 46/12% of patients in the L-OHP group, and 100/0% in the CDDP group. The worst grades of chemotherapy-induced PN during 2nd-PTX were grades 1/2/3 in 40/34/14% of patients in the L-OHP group, and 36/18/0% in the CDDP group. Median time to grade 2 PN after starting second-PTX was 2.5 months in the L-OHP group and 8.6 months in the CDDP group (hazard ratio 3.34, p = 0.002). The frequencies of a PN-related dose reduction and/or discontinuation of PTX were 18% in the L-OHP group and 8% in the CDDP group (p = 0.234).

Conclusions

The severity of PN and tolerability of 2nd-PTX may be affected by first-line chemotherapy with L-OHP or CDDP for AGC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Japanese Gastric Cancer Association (2018) Japanese gastric cancer treatment guidelines (ver. 5), Tokyo, Japan. Japanese Gastric Cancer Association, Tokyo

    Google Scholar 

  2. Blumenthal DT (2009) Assessment of neuropathy pain in cancer patients. Curr Pain Headache Rep 13(4):282–287

    Article  Google Scholar 

  3. Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15–49

    Article  CAS  Google Scholar 

  4. Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs. https://doi.org/10.1016/j.soncn.2009.03.013

    Article  PubMed  Google Scholar 

  5. Argyriou AA, Polychronopoulos P, Iconomou G et al (2007) Incidence and characteristics of peripheral neuropathy during oxaliplatin based chemotherapy for metastatic colon cancer. Acta Oncol 46(8):1131–1137

    Article  CAS  Google Scholar 

  6. Hilkens PH, ven den Bent MJ (1997) Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 2(4):350–361

    PubMed  CAS  Google Scholar 

  7. Thompson SW, Davis LE, Kornfeld M (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54(7):1269–1275

    Article  CAS  Google Scholar 

  8. Gregg RW, Molepo JM, Monpetit VJ et al (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10(5):795–803

    Article  CAS  Google Scholar 

  9. Glendenning JL, Barbachano Y, Norman AR et al (2010) Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116(10):2322–2331

    PubMed  CAS  Google Scholar 

  10. van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW et al (1990) Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66(8):1697–1702

    Article  Google Scholar 

  11. Cavaletti G, Marzorati L, Bogliun G et al (1992) Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 69(1):203–207

    Article  CAS  Google Scholar 

  12. Mollman JE, Glover DJ, Hogan WM et al (1988) Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61(11):2192–2195

    Article  CAS  Google Scholar 

  13. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947

    Article  Google Scholar 

  14. Souglakos J, Mavroudis D, Kakolyris S et al (2002) Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 20(11):2651–2657

    Article  CAS  Google Scholar 

  15. Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 26(1):141–148

    Article  CAS  Google Scholar 

  16. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46

    Article  CAS  Google Scholar 

  17. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442

    Article  CAS  Google Scholar 

  18. Park SB, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA cancer J Clin 63(6):419–437

    Article  Google Scholar 

  19. Kang JH, Lee SI, Lim DH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13):1513–1518

    Article  CAS  Google Scholar 

  20. Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35):4438–4444

    Article  CAS  Google Scholar 

  21. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452–458

    Article  CAS  Google Scholar 

  22. Pachman DR, Qin R, Seisler DK et al (2015) Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol 33(30):3416–3422

    Article  CAS  Google Scholar 

  23. Yamaguchi K, Kusaba H, Makiyama A et al (2018) The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Cancer Chemother Pharmacol 82(4):625–633

    Article  CAS  Google Scholar 

  24. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17

    Article  CAS  Google Scholar 

  25. Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20(4):767–775

    Article  CAS  Google Scholar 

  26. Loprinzi CL, Qin R, Dakhil SR et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32(10):997–1005

    Article  CAS  Google Scholar 

  27. Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40(7):872–882

    Article  CAS  Google Scholar 

  28. Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632

    Article  Google Scholar 

  29. Iizumi S, Takashima A, Sakamaki K et al (2018) Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol 81(6):981–989

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan

    Ryo Otsuka, Takako Yanai, Hironobu Hashimoto, Masatoshi Sekiguchi, Yoshinori Makino & Masakazu Yamaguchi

  2. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Satoru Iwasa, Hidekazu Hirano, Hirokazu Shoji, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato & Narikazu Boku

Authors
  1. Ryo Otsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Iwasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takako Yanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hidekazu Hirano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirokazu Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Natsuko Okita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsuo Takashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hironobu Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masatoshi Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshinori Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Narikazu Boku
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masakazu Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Narikazu Boku.

Ethics declarations

Conflict of interest

No author has any conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Otsuka, R., Iwasa, S., Yanai, T. et al. Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer. Int J Clin Oncol 25, 595–601 (2020). https://doi.org/10.1007/s10147-019-01598-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-019-01598-5

Keywords

Search

Navigation